文献速递头颈外科

头颈组织移植重建的ERAS方案减少阿片类药物使用、峰值疼痛评分和输血需求

ERAS for Head and Neck Tissue Transfer Reduces Opioid Usage, Peak Pain Scores, and Blood Utilization.
PubMed 文献 · Laryngoscope · 2020-06-09

本研究回顾性比较132例ERAS与66例非ERAS头颈癌组织移植重建患者,ERAS方案包括术前非阿片类药物负荷、全静脉麻醉、多模式围手术期镇痛和限制性红细胞输注;结果显示ERAS组术后峰值疼痛评分、阿片类药物用量和红细胞输注率更低,且住院时间、ICU时间、并发症和30天再入院率无差异。

要点

  • ERAS方案可降低头颈组织移植重建术后疼痛评分和阿片类药物用量。
  • ERAS组红细胞输注单位数低于非ERAS组,且不增加住院时间或并发症。
  • 该回顾性研究证据等级为3级,需前瞻性研究进一步验证。

核心结论

  • ERAS路径可减少头颈癌重建术后疼痛、阿片类药物使用和红细胞输注,且不增加住院或ICU时间、并发症及再入院率。

研究设计与样本

  • 回顾性队列研究,比较132例ERAS与66例非ERAS头颈癌组织移植重建患者,数据由两个团队双盲收集。

主要发现

  • 两组住院时间、ICU时间、并发症率和30天再入院率无差异。

临床怎么用

  • 对于头颈组织移植重建患者,可考虑实施包含术前非阿片类药物负荷、全静脉麻醉、多模式镇痛和限制性输血的ERAS方案。

局限性

  • 回顾性队列研究,证据等级为3级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We implement a novel enhanced recovery after surgery (ERAS) protocol with pre-operative non-opioid loading, total intravenous anesthesia, multimodal peri-operative analgesia, and restricted red blood cell (pRBC) transfusions. 1) Compare differences in mean postoperative peak pain scores, opioid usage, and pRBC transfusions. 2) Examine changes in overall length of stay (LOS), intensive care unit LOS, complications, and 30-day readmissions. METHODS: Retrospective cohort study comparing 132 ERAS vs. 66 non-ERAS patients after HNC tissue transfer reconstruction. Data was collected in a double-blind fashion by two teams. RESULTS: Mean postoperative peak pain scores were lower in the ERAS group up to postoperative day (POD) 2. POD0: 4.6 ± 3.6 vs. 6.5 ± 3.5; P = .004) (POD1: 5.2 ± 3.5 vs. 7.3 ± 2.3; P = .002) (POD2: 4.1 ± 3.5 vs. 6.6 ± 2.8; P = .000). Opioid utilization, converted into morphine milligram equivalents, was decreased in the ERAS group (POD0: 6.0 ± 9.8 vs. 10.3 ± 10.8; P = .010) (POD1: 14.1 ± 22.1 vs. 34.2 ± 23.2; P = .000) (POD2: 11.4 ± 19.7 vs. 37.6 ± 31.7; P = .000) (POD3: 13.7 ± 20.5 vs. 37.9 ± 42.3; P = .000) (POD4: 11.7 ± 17.9 vs. 36.2 ± 39.2; P = .000) (POD5: 10.3 ± 17.9 vs. 35.4 ± 45.6; P = .000). Mean pRBC transfusion rate was lower in ERAS patients (2.1 vs. 3.1 units, P = .017). There were no differences between ERAS and non-ERAS patients in hospital LOS, ICU LOS, complication rates, and 30-day readmissions. CONCLUSION: Our ERAS pathway reduced postoperative pain, opioid usage, and pRBC transfusions after HNC reconstruction. These benefits were obtained without an increase in hospital or ICU LOS, complications, or readmission rates. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E792-E799, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Clark BS, Swanson M, Widjaja W, et al. ERAS for Head and Neck Tissue Transfer Reduces Opioid Usage, Peak Pain Scores, and Blood Utilization. Laryngoscope. 2020. PMID: 32516508. doi:10.1002/lary.28768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。